FDA warned Quality CDMO that its prescription skin and scalp drugs are unapproved and lack FDA-approved applications.
What happened
FDA inspected Quality CDMO’s Fort Worth, TX drug manufacturing facility from June 12 to 16, 2023, and then reviewed the firm’s website and product labeling. FDA found five prescription drug products with labeled uses such as treating dermatitis, acne, dandruff, psoriasis, and skin cracks, but no FDA-approved applications were in effect for them.
What FDA found
The five products are drugs because their labels say they treat diseases or affect the body.
section 201(g)(1)(B) and/or (C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) and/or (C)FDA considers the products new drugs because they are not generally recognized as safe and effective for their labeled uses.
section 201(p)(1) of the FD&C Act, 21 U.S.C. 321(p)(1)The firm introduced or delivered for introduction into interstate commerce these unapproved new drugs without an FDA-approved application.
sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA tells the company to stop marketing all of the unapproved prescription drugs immediately and to contact CDER’s Drug Shortages Staff about any discontinuances or interruptions. It must respond in writing within 15 working days with corrective steps, supporting documents, and any eDRLS listing updates, or explain why it believes the products are not violations.
Who should pay attention
- pharmacies and prescribers who buy these products
- brands and distributors sourcing from Quality CDMO
- other firms listing similar unapproved prescription skin drugs
This is a summary. Read the original letter on fda.gov.